Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China
{{output}}
Background and objective: Secukinumab (SEC), an interleukin 17A inhibitors (IL-17Ai) has been shown to be effective in managing axial spondyloarthritis (axSpA). However, data on its long-term retention in Chinese populations rema... ...
